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1. Introduction 
Most of the discussions on cardiovascular diseases include the relative level of total plasma 
cholesterol whereas complete lipid profile is very important as clinical diagnotics for 
cardiovascular risk. For example, the status of triglycerides, low density lipoprotein cholesterol 
(LDL cholesterol), high density lipoprotein cholesterol (HDL cholesterol), thyroid functions, 
insulin and lipid peroxides etc as these lipids are related to cardiovascular disease either as 
markers of another underlying disturbance or along the same pathways of cholesterol 
metabolism. According to latest World Health Organization (WHO) report about 50% of the 
heart attacks occur in individual with high level of cholesterol. The most abundant sterol in 
animal system is in the form of cholesterol whereas plants lack cholesterol but they contain 
structurally similar other sterol and similar biosynthetic pathway exist both in plants and 
animals as well as some prokaryotes also synthesize some specific sterols. In 1948, the 
Framingham Heart Study - under the direction of the National Heart Institute (now known as 
the National Heart, Lung, and Blood Institute or NHLBI) - embarked on an ambitious project 
in health research. At the time, little was known about the general causes of heart disease and 
stroke, but the death rates for CVD had been increasing steadily since the beginning of the 
century and had become an American epidemic. The Framingham Heart Study became a joint 
project of the National Heart, Lung and Blood Institute and Boston University. The concern 
about cholesterol was largely fueled by this study and others that provided strong evidence 
that when large populations are observed, persons with higher than average serum total 
cholesterol have a higher incidence of coronary artery disease (CAD). Laboratory reports often 
mention two main types of cholesterol, the HDL cholesterol (often termed the "good" 
cholesterol) and LDL cholesterol (often mis-named the "bad" one. Even if the total LDL is 
lowered, the important fraction is actually the small LDL, which is more easily oxidized into a 
potentially atherogenic particle than its larger, more buoyant counterpart. Bacteria or other 
infectious agents are being looked at as part of the culprits as causative factors in initiating 
injury to the arterial wall. Cholesterol is then attracted to this ‘rough’ site on the blood vessel 
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wall in an attempt to heal the wall so that blood will flow smoothly over the injured area. 
Cholesterol itself is not the cause of CAD. The blood cholesterol is rather only a reflection of 
other metabolic imbalances in the vast majority of cases. If we assume blood lipid (fats) status 
are associated with some risk of cardiovascular disease. The question is which lipids are the 
important markers, and even more important what should we do about them.  
Lowering cholesterol too aggressively or in artificial circumstances or having too low total 
cholesterol is also undesirable. Plasma cholesterol level below 200mg% is desirable whereas as 
200-239mg% and above 240mg% is considered as borderline and high level of cholesterol, 
respectively. Ingested cholesterol comes from animal sources (plants and prokaryotes do not 
contain cholesterol (Gylling and Miettinen, 1995) such as eggs, meat, dairy products, fish, and 
shellfish or biosynthesized from the breakdown of carbohydrates, lipids, or proteins available 
in the food. One study has estimated that the complete abolition of dietary cholesterol 
absorption would reduce plasma cholesterol by up to 62% (Gylling and Miettinen, 1995). 
About 50% of dietary cholesterol is absorbed through intestinal enterocytes, while the rest is 
excreted through feces (Ostlund et al., 1999). It is estimated that half of ingested cholesterol 
enters the body while the other half excreated in the feces. Normally, the more cholesterol we 
absorb, the less our bodies make. There is slight increase in plasma cholesterol with increase in 
the amount of cholesterol ingested each day, usually is not changed more than  15 percent by 
altering the amount of cholesterol in the diet. Although the response of individuals differs 
markedly. Cholesterol is integeral part of membranes and perform a number of vital functions 
in the cell and due to this property of cholesterol, each cell has the capability to biosynthesize 
cholesterol if it is required. Cholesterol is a component of steroid hormones, including 
pregnenolone, estrogens, progesterone, testosterone, vitamin D and bile acids. Bile acids are 
involved in lipid digestion, absorption, and excretion.  
In this chapter, mode of intracellular and extracellular cholesterol transport through 
acceptors-donors and thereafter cholesterol trafficking pathways will be described in detail. 
Furthermore, we will discuss the regulation of cholesterol at enzymatic/transcriptional level 
and diverse functions of cholesterol in our body. Taken together, this book chapter will 
address recent advances in cholesterol metabolism both in vitro and in vivo models related to 
absorptions, biosynthesis, transport, excretion and therapeutic targets for new drugs and 
natural compounds.  
1.1 Cholesterol biosynthetic pathway  
As early as 1926, studies by Heilbron, Kamm and Owens suggested that squalene is 
precursor of cholesterol biosynthesis (Garrett & Grisham, 2007). In the same year, H.J. 
Channon, demonstrated first time that animals fed on shark oil produced more cholesterol 
in the tissues. In 1940, Bloch and Rittenberg, first time demonstrated that mice fed on 
radiolabled acetate showed significant radiolabeled cholesterol (Bloch et al., 1945; Kresge et 
al., 2005). In 1952, Konard Bloch and Robert Langdon showed conclusively that squalene as 
well as cholesterol are synthesized from acetate for which Fyodor Lynen and Bloch were 
awarded the Noble Prize in Medicine/Physiology in 1964. Cholesterol is biosynthesized 
from 2-carbon metabolic intermediate, acetyl-CoA hooked end to end involving a number of 
enzymatic reactions and finally get converted into the 27-carbon molecule of cholesterol. 
Metabolism (catabolism) of lipids, carbohydrates and proteins lead to the formation Acetyl-
CoA. Proteins are generally are not catabolized for the purpose of energy and usually 
broken down into amino acids for denovo protein biosynthesis, under excessive protein 
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consumption or during certain disease states, certain proteins can be catabolized to acetyl-
CoA. Non-essential fatty acids, trans-fatty acids, and saturated fats, and refined 
carbohydrates are general source of excessive acetyl-CoAwhich pressurize our body to 
biosynthesize cholesterol. In other words, cholesterol is formed from excess calories which 
usually are generated most often from carbohydrates and fats.  
1= Mevalonate kinase
2= Phosphomevalonate kinase
3=Pyrophosphomevalonate decarboxylase
4= Isopentenyl pyrophosphate isomerase
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Fig. 1. Cholesterol Biosynthetic Pathway 
The process of cholesterol synthesis has five major steps: 
1. Acetyl-CoAs are converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)  
2. HMG-CoA is converted to mevalonate 
3. Mevalonate is converted to the isoprene based molecule, isopentenyl pyrophosphate 
(IPP), with the concomitant loss of CO2 
4. IPP is converted to squalene 
5. Squalene is converted to cholesterol.  
Acetyl-CoA units are converted to mevalonate by a series of reactions that begins with the 
formation of HMG-CoA (Figure 1). Unlike the HMG-CoA formed during ketone body 
synthesis in the mitochondria, this form is synthesized in the cytoplasm. However, the 
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pathway and the necessary enzymes are the same as those in the mitochondria. Two moles 
of acetyl-CoA are condensed in a reversal of the thiolase reaction, forming acetoacetyl-CoA. 
Acetoacetyl-CoA and a third mole of acetyl-CoA are converted to HMG-CoA by the action 
of HMG-CoA synthase. HMG-CoA is converted to mevalonate by HMG-CoA reductase, 
HMGR (this enzyme is bound in the endoplasmic reticulum, ER). HMGR absolutely 
requires NADPH as a cofactor and two moles of NADPH are consumed during the 
conversion of HMG-CoA to mevalonate. The reaction catalyzed by HMGR is the rate 
limiting step of cholesterol biosynthesis, and this enzyme is subject to complex regulatory 
controls which will be discussed in separate section of this book chapter.  
lanosterol 14α-demethylase
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Fig. 2. Post squalene pathway of cholesterol and other sterol Biosynthesis 
Mevalonate is then activated by three successive phosphorylations, yielding 5-
pyrophosphomevalonate. Phosphorylation mevalonate and successive reactions maintain its 
solubility, since otherwise these are insoluble in water. After phosphorylation, an ATP-
dependent decarboxylation yields isopentenyl pyrophosphate, IPP, an activated isoprenoid 
molecule. Isopentenyl pyrophosphate is in equilibrium with its isomer, dimethylallyl 
pyrophosphate, DMPP. One molecule of IPP condenses with one molecule of DMPP to 
generate geranyl pyrophosphate, GPP. GPP further condenses with another IPP molecule to 
yield farnesyl pyrophosphate, FPP. Finally, the NADPH-requiring enzyme, squalene 
synthase catalyzes the head-to-tail condensation of two molecules of FPP, yielding squalene 
(squalene synthase also is tightly associated with the endoplasmic reticulum). Squalene 
undergoes a two step cyclization to yield lanosterol catalyzed by sequalene mono- 
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oxygenase and sequalene 2, 3 epoxidase enzymes. Sequalene mono oxygenase is the second 
committed step in cholesterol biosynthesis and lead to the formation squalene 2, 3 epoxide. 
This enzymatic reaction require supernatant protein factor (SPF) and NADPH as a cofactor 
to introduce molecular oxygen as an epoxide at the 2, 3 position of squalene. The activity of 
supernatant protein factor itself is regulated by phosphorylation/dephosphorylation (Singh 
et al., 2003). Through a series of 19 additional reactions, lanosterol is converted to 
cholesterol. The first sterol intermediate, lanosterol, is formed by the condensation of the 30 
carbon isoprenoid squalene as explained above and figure 1., and subsequent enzymatic 
reactions define the ‘post-squalene’ half of the pathway figure 2. 
The conversion of lanosterol to cholesterol involves the reduction of the C-24 double bond, 
removal of three methyl groups at the C-14 and C-4 positions, and ‘migration’ of the C-8(9) 
double bond (Figure 2) (for a review, see (Herman, 2003)). Some of the enzymatic reactions 
must occur in sequence; for example, Δ8–Δ7 isomerization cannot precede C-14ǂ 
demethylation. The saturation of the C-24 double bond of lanosterol can occur at multiple 
points in the pathway, creating two immediate precursors for cholesterol, desmosterol 
[cholesta-5(6), 24-dien-3ǃ-ol] and 7-dehydrocholesterol (7DHC), whose relative abundance 
may vary among different tissues. Desmosterol, in particular, appears to be abundant in the 
developing mammalian brain (Herman, 2003). Several post-squalene sterol intermediates 
serve additional cellular functions as well. The C-14 demethylated derivatives of lanosterol, 
4,4-dimethyl-5ǂ-cholesta-8,14,24-trien-3ǃ-ol and 4,4-dimethyl-5ǂ-cholesta-8,24-dien-3ǃ-ol, 
have meiosis-stimulating activity and accumulate in the ovary and testis, respectively 
(Rozman et al., 2002). 7-Dehydrocholesterol is the immediate precursor for vitamin D 
synthesis. Selected human enzymes of post-squalene cholesterol biosynthesis have also been 
identified based on homology to sterol biosynthetic enzymes from Arabidopsis thaliana 
(Herman, 2003; Waterham et al., 2001). In addition, cholesterol and other sterol 
intermediates can be converted to oxysterols that can act as regulatory signaling molecules 
and bind orphan nuclear receptors such as LXRǂ (Fitzgerald et al., 2002).  
Normal healthy adults synthesize cholesterol at a rate of approximately 1g/day and 
consume approximately 0.3g/day. A relatively constant level of cholesterol in the body (150 
- 200 mg/dL) is maintained primarily by controlling the level of de novo synthesis which is 
partly regulated in part by the dietary intake of cholesterol. Cholesterol from both diet and 
synthesis is utilized in the formation of membranes and in the synthesis of the steroid 
hormones and bile acids. The greatest proportion of cholesterol is used in bile acid synthesis. 
1.1.1 Regulation of cholesterol biosynthetic pathway  
Regulation of the pathway includes sterol-mediated feedback of transcription of several of 
the genes, including the rate-limiting enzyme HMGR and HMG-CoA synthase, as well as a 
variety of post-transcriptional mechanisms. Recently, increased attention has been focused 
on the regulated degradation of HMGR in the ER. The cellular supply of cholesterol is 
maintained at a steady level by four distinct mechanisms:  
1. Regulation of HMGR activity and levels (upstream regulation of cholesterol 
biosynthesis) 
2. Regulation of sequalene mono-oxygenase activity by sequalene supernant protein factor 
(down stream biosynthesis of cholesterol). Once this step is taken place then it ends up 
biosynthesis of cholesterol.  
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3. Regulation of excess intracellular free cholesterol through the activity of acyl-CoA: 
cholesterol acyltransferase, ACAT (internalization of excessive cholesterol). 
4. Regulation of plasma cholesterol levels via LDL receptor-mediated uptake and HDL-
mediated reverse transport.  
The first seven enzymes of cholesterol biosynthesis are soluble proteins with the exception 
of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR), which is an integral endoplasmic 
reticulum (ER) membrane protein (Gaylor, 2002; Goldstein and Brown, 1990; Kovacs et al., 
2002). HMG-CoA for cholesterol biosynthesis is generated within the cytosol. It is also 
synthesized within the mitochondria where its hydrolysis by HMG-CoA lyase generates 
ketones for energy during fasting (Herman, 2003). Reactions generating mevalonate can also 
occur within the peroxisome, and the subsequent reactions that result in the production of 
farnesyl-pyrophosphate are exclusively peroxisomal. The remainder of the biosynthetic 
reactions occurs in the ER with enzymes and substrates that are membrane-bound. Thus, 
cholesterol biosynthetic enzymes are compartmentalized in the cytosol, ER and/or 
peroxisome, adding another level of complexity to the regulation of this metabolic pathway. 
Particularly, direct regulation of HMGCoA reductase activity means for controlling the level 
of cholesterol biosynthesis. Recently, increased attention has been focused on the regulated 
degradation of HMGR in the ER.  
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Fig. 3. Regulation of HMGCoA reductase 
In vivo system, the activity of HMGCoA reductase is controlled by four distinct mechanisms: 
feed-back inhibition, control of gene expression, rate of enzyme degradation and 
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phosphorylation-dephosphorylation. Cholesterol controls the first three mechanisms itself 
as cholesterol acts as a feed-back inhibitor of pre-existing HMGR as well as inducing rapid 
degradation of the enzyme. The latter is the result of cholesterol-induced polyubiquitination 
of HMGR and its degradation in the proteosome (explained in separate section in details). 
This ability of cholesterol is a consequence of the sterol sensing domain, SSD of HMGR. In 
addition, when cholesterol is in excess the amount of mRNA for HMGR is reduced as a 
result of decreased expression of the gene. By covalent modification of HMGreductase 
through the process phosphorylation/ dephosphorylation plays a very important role in 
regulation of HMGR. The enzyme is most active in its unmodified form. Phosphorylation of 
the enzyme decreases its activity (Figure 3). HMGR is phosphorylated by adenosine mono 
phosphate-activated protein kinase, (AMPK)which is itself activated via phosphorylation 
catalyzed by 2 enzymes. LKB1 is the primary kinase sensitive to rising AMP levels which 
was first identified as a gene in humans carrying an autosomal dominant mutation in Peutz-
Jeghers syndrome, PJS and mutated in lung adenocarcinomas. The second AMPK 
phosphorylating enzyme is calmodulin-dependent protein kinase kinase-beta (CaMKKǃ) 
which induces phosphorylation of AMPK due to increase in the level of intracellular Ca2+ as 
a result of muscle contraction. The activity of HMGR is additionally controlled by the cAMP 
signaling pathway (Figure 3). Enhanced level of cAMP lead to activation of cAMP-
dependent protein kinase, PKA. In the context of HMGR regulation, PKA phosphorylates 
phosphoprotein phosphatase inhibitor-1 (PPI-1) leading to an increase in its activity. PPI-1 
can inhibit the activity of numerous phosphatases including protein phosphatase 2C (PP2C) 
and HMG-CoA reductase phosphatase which remove phosphates from AMPK and HMGR, 
respectively. This maintains AMPK in the phosphorylated and active state, and HMGR in 
the phosphorylated and inactive state. As the stimulus leading to increased cAMP 
production is removed, the level of phosphorylations decreases and that of 
dephosphorylations increases. The net result is a return to a higher level of HMGR activity. 
The intracellular level of cAMP itself is regulated by hormonal stimuli, thus regulation of 
cholesterol biosynthesis is hormonally controlled. One of the most common hormone, 
insulin leads to a decrease in cAMP, which in turn activates cholesterol biosynthesis. 
Alternatively, glucagon and epinephrine increase the level of cAMP in turn lead to 
inhibition of cholesterol biosynthesis. The basic function of epinephrine and glucagon 
hormones is to control the availability and delivery of energy in all the cells in our body. 
Degradation of HMGR and inhibition of its biosynthesis, are the two long term regulatory 
processes for cholesterol biosynthesis as when the levels of cholesterol are high, resulted in 
reduction in the expression of the HMGR gene. On other hand, low levels of cholesterol 
activate its expression.  
1.1.2 Proteolytic regulation of HMG-CoA  
The stability of HMGR is regulated as the rate of flux through the mevalonate synthesis 
pathway changes. When the flux is high the rate of HMGR degradation is also high. When 
the flux is low, degradation of HMGR decreases. This phenomenon can easily be observed 
in the presence of the statin drugs. HMGR is localized to the ER and like SREBP contains a 
sterol-sensing domain, SSD. When sterol levels increase in cells there is a concomitant 
increase in the rate of HMGR degradation. The degradation of HMGR occurs within the 
proteosome, multiprotein complex dedicated for protein degradation.The primary signal 
directing proteins to the proteosome is ubiquitination. Ubiquitin is a 7.6kDa protein that is 
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covalently attached to proteins targeted for degradation by ubiquitin ligases (Kimura and 
Tanaka, 2010). These enzymes attach multiple copies of ubiquitin allowing for recognition 
by the proteosome. HMGR has been shown to be ubiquitinated prior to its degradation. The 
primary sterol regulating HMGR degradation is cholesterol itself. As the levels of free 
cholesterol increase in cells, the rate of HMGR degradation increases.  
1.2 Disorders of post-sequalene cholesterol biosynthesis 
Seven disorders (Smith-Lemli-Opitz, desmosterolosis, X-linked dominant chondrodysplasis 
punctata, child syndrome, lathosterolosis and hydrops-ectopic calcification-moth-eaten 
skeletal dysplasia) of post-squalene cholesterol biosynthesis have been reported, only the 
most commonly disorder, Smith-Lemli-Opitz syndrome (SLOS) will be discussed in this 
section of the book as described and reviewed else where (Herman, 2003). SLOS was the 
first described disorder of post-squalene cholesterol biosynthesis and is by far the most 
common, with an incidence of approximately 1/40 000 to 1/50 000 in the USA (reviewed in 
(Kelley and Hennekam, 2000). It was initially described in 1964 as an autosomal recessive 
major malformation syndrome. In 1993, Irons et al.(Irons et al., 1993) detected decreased 
plasma cholesterol levels and elevated 7DHC in several patients with SLOS, suggesting an 
enzymatic efficiency of 7-dehydrocholesterol reductase (7DHCR).  
1.3 Regulation of cholesterol biosynthesis at transcriptional level 
As cells need more sterol they will induce their synthesis and uptake, conversely when the 
need declines synthesis and uptake are decreased. Regulation of these events is brought 
about primarily by sterol-regulated transcription of key rate limiting enzymes and by the 
regulated degradation of HMGR. Activation of transcriptional control occurs through the 
regulated cleavage of the membrane-bound transcription factor sterol regulated element 
binding protein (SREBP). As discussed earlier in this book chapter, degradation of HMGR 
is controlled by the ubiquitin-mediated pathway for proteolysis. Sterol control of 
transcription affects more than 30 genes involved in the biosynthesis of cholesterol, 
triacylglycerols, phospholipids and fatty acids. Transcriptional control requires the presence 
of an octamer sequence in the gene termed the sterol regulatory element-1 (SRE-1). It has 
been shown that SREBP is the transcription factor that binds to SRE-1 elements. It turns out 
that there are 2 distinct SREBP genes, SREBP-1 and SREBP-2. In addition, the SREBP-1 gene 
encodes 2 proteins, SREBP-1a and SREBP-1c/ADD1 (ADD1 is adipocyte differentiation-1) as 
a consequence of alternative exon usage. SREBP-1a regulates all SREBP-responsive genes in 
both the cholesterol and fatty acid biosynthetic pathways. SREBP-1c controls the expression 
of genes involved in fatty acid synthesis and is involved in the differentiation of adipocytes. 
SREBP-1c is also an essential transcription factor downstream of the actions of insulin at the 
level of carbohydrate and lipid metabolism. SREBP-2 is the predominant form of this 
transcription factor in the liver and it exhibits preference at controlling the expression of 
genes involved in cholesterol homeostasis, including all of the genes encoding the sterol 
biosynthetic enzymes. In addition SREBP-2 controls expression of the LDL receptor gene.  
Regulated expression of the SREBPs is complex in that the effects of sterols are different on 
the SREBP-1 gene versus the SREBP-2 gene. High sterols activate expression of the SREBP-1 
gene but do not exert this effect on the SREBP-2 gene. The sterol-mediated activation of the 
SREBP-1 gene occurs via the action of the liver X receptors (LXRs). The LXRs are members 
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of the steroid/ thyroid hormone super family of cytosolic ligand binding receptors that 
migrate to the nucleus upon ligand binding and regulate gene expression by binding to 
specific target sequences. There are two forms of the LXRs: LXRǂ and LXRǃ. The LXRs form 
heterodimers with the retinoid X receptors (RXRs) and as such can regulate gene expression 
either upon binding oxysterols (e.g. 22R-hydroxycholesterol) or 9-cis-retinoic acid. All 3 
SREBPs are proteolytically activated and the proteolysis is controlled by the level of sterols 
in the cell. Full-length SREBPs have several domains and are embedded in the membrane of 
the endoplasmic reticulum (ER). The N-terminal domain contains a transcription factor 
motif of the basic helix-loop-helix (bHLH) type that is exposed to the cytoplasmic side of the 
ER. There are 2 transmembrane spanning domains followed by a large C-terminal domain 
also exposed to the cytosolic side. The C-terminal domain (CTD) interacts with a protein 
called SREBP cleavage-activating protein (SCAP). SCAP is a large protein also found in the 
ER membrane and contains at least 8 transmembrane spans. The C-terminal portion, which 
extends into the cytosol, has been shown to interact with the C-terminal domain of SREBP. 
This C-terminal region of SCAP contains 4 motifs called WD40 repeats. The WD40 repeats 
are required for interaction of SCAP with SREBP. The regulation of SREBP activity is further 
controlled within the ER by the interaction of SCAP with insulin regulated protein (Insig). 
When cells have sufficient sterol content SREBP and SCAP are retained in the ER via the 
SCAP-Insig interaction. The N-terminus of SCAP, including membrane spans 2–6, resembles 
HMGR which itself is subject to sterol-stimulated degradation (see above). This shared motif 
is called the sterol sensing domain (SSD) and as a consequence of this domain SCAP 
functions as the cholesterol sensor in the protein complex. When cells have sufficient levels 
of sterols, SCAP will bind cholesterol which promotes the interaction with Insig and the 
entire complex will be maintained in the ER.  
The Insig proteins bind to oxysterols which in turn affects their interactions with SCAP. 
Insig proteins can cause ER retention of the SREBP/SCAP complex. In addition to their role 
in regulating sterol-dependent gene regulation, both Insig proteins activate sterol-
dependent degradation of HMGR. 
When sterols are scarce, SCAP does not interact with Insig. Under these conditions the 
SREBP-SCAP complex migrates to the Golgi where SREBP is subjected to proteolysis. The 
cleavage of SREBP is carried out by 2 distinct enzymes. The regulated cleavage occurs in the 
lumenal loop between the 2 transmembrane domains. This cleavage is catalyzed by site-1 
protease, S1P. The function of SCAP is to positively stimulate S1P-mediated cleavage of 
SREBP. The second cleavage, catalyzed by site-2 protease, S2P, occurs in the first 
transmembrane span, leading to release of active SREBP. In order for S2P to act on SREBP, 
site-1 must already have been cleaved. The result of the S2P cleavage is the release of the N-
terminal bHLH motif into the cytosol. The bHLH domain then migrates to the nucleus 
where it will dimerize and form complexes with transcriptional coactivators leading to the 
activation of genes containing the SRE motif. To control the level of SREBP-mediated 
transcription, the soluble bHLH domain is itself subject to rapid proteolysis.  
1.4 Interaction of cholesterol with other lipids  
Cholesterol plays a vital role in determining the physiochemical properties of cell 
membranes. However, the detailed nature of cholesterol–lipid interactions is a subject of 
ongoing debate. Cholesterol primarily serves as a structural component of cellular 
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membranes. When incorporated into phospholipid bilayers, cholesterol aligns so that its 
polar hydroxyl group is near the interface with the aqueous environment while its 
hydrophobic body is buried in the bilayer (Ohvo-Rekila et al., 2002; Olsen et al., 2011a; Olsen 
et al., 2011b). The interaction of cholesterol with neighboring phospholipids alters 
membrane structure. The alignment and ordering of nearby phospholipid tails causes 
membrane condensation, decreasing the area of the membrane and increasing the thickness 
(Ohvo-Rekila et al., 2002). Cholesterol also broadens the liquid-to-solid phase transition, 
inducing an intermediate liquid-ordered phase that retains lateral mobility while increasing 
lipid order (Feigenson, 2007; Simons and Vaz, 2004; van Meer et al., 2008). These changes 
result in a mechanically stronger membrane with decreased permeability due to tighter 
packing among lipids (Ikonen, 2008; Simons and Vaz, 2004). The low activity pool consists 
of cholesterol that is sequestered within the phospholipids and relatively inaccessible to 
other molecules, while the high activity pool of cholesterol that is more accessible and 
mobile in the non-condensed phospholipids of the membrane (Olsen et al., 2011b). 
Distribution between the high and low activity pools is determined by the ability of the 
phospholipids to condense with cholesterol, which in turn is dependent on the phospholipid 
composition of the membrane. Thus, raising the plasma membrane cholesterol concentration 
can saturate the ability of the membrane to accommodate cholesterol in the condensed 
phospholipids, whereupon excess cholesterol transitions into the high activity pool where it is 
more available for trafficking to the ER. Sphingomyelin is other important lipid present in the 
biomembrane that interact with cholesterol (Garmy et al., 2005). Interaction between 
cholesterol and sphingomyelin has a very high biological significance as lipid-lipid interaction 
leads to the formation of ordered lipid domains in the plasma membrane of eukaryotic cells 
(Simons and Ikonen, 1997). Molecular association between cholesterol and sphingomyelin is 
very important as this constitute cholesterol enriched microdomains of plasma membrane and 
plays a very important role in cellular functions such as the control of signal transduction 
pathways. On the other hand, the formation of cholesterol-sphingomyelin molecular 
complexes in the intestinal lumen explains the mutual inhibitory effects of cholesterol and 
sphingomyelin on their intestinal absorption (Nyberg et al., 2000). 
1.5 Cholesterol homeostasis 
Every eukaryotic cell require cholesterol as its not only integral part of membrane as well as 
plays very important role in cell signalling pathways. That the reason, all eukaryotic cells, 
which have specialized methods of recruiting and synthesizing the cholesterol only when it 
is needed. While effectively maintaining intracellular cholesterol homeostasis, these 
processes leave excess circulating though the body, leading to atherosclerotic plaque 
development and subsequent coronary artery disease. Thus, levels of cholesterol and related 
lipids circulating in plasma are important predictive tools utilized clinically to diagnose the 
risk of a cardiovascular diseases (Daniels et al., 2009; Ikonen, 2008; Simons and Ikonen, 2000; 
Singh et al., 2007). Cholesterol is transported in the plasma predominantly as cholesteryl 
esters associated with lipoproteins and dietary cholesterol is transported from the small 
intestine to the liver in the form of chylomicrons. Cholesterol synthesized by the liver, as 
well as any dietary cholesterol in the liver that exceeds hepatic needs, is transported in the 
serum in the form of low density lipoproteins (LDLs). In the liver, VLDLs are 
biosyntheiszed and are converted to LDLs by endothelial cell-associated lipoprotein lipase. 
High density lipoproteins (HDLs)can extract Cholesterol found in plasma membranes and 
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esterified by the HDL-associated enzyme LCAT. The cholesterol acquired from peripheral 
tissues by HDLs can then be transferred to VLDLs and LDLs via the action of cholesteryl ester 
transfer protein (apo-D) which is associated with HDLs. In humans, HDL levels are a very 
well known measurement of cardiac health due to their strong inverse relationship with 
coronary artery disease. Peripheral cholesterol is returned to the liver by the process called 
reverse cholesterol transport by HDLs and ultimately, cholesterol is excreted in the bile as 
free cholesterol or as bile salts following conversion to bile acids in the liver (Figure 4).  
 
Fig. 4. Cholesterol homeostasis 
1.6 Cholesterol and ion channels  
A number of studies has demonstrated that the level of membrane cholesterol regulate the 
ion channel functions (Levitan et al., 2010; Maguy et al., 2006; Martens et al., 2004). The impact 
of cholesterol on different types of ion channels is highly heterogeneous. In most of the cases 
cholesterol supresses channel activity that may include decrease in the open probability, 
unitary conductance and/or the number of active channels on the membrane. This effect 
was observed in several types of K+ channels, voltage-gated Na+ and Ca+2 channels, as well 
as in volume-regulated anion channels. However, there are also several types of ion 
channels, such as epithelial Na+ channels (eNaC) and transient receptor potential (Trp) 
channels that are inhibited by the removal of membrane cholesterol. Finally, in some cases 
changes in membrane cholesterol affect biophysical properties of the channel such as the 
voltage dependence of channel activation or inactivation. Clearly, therefore, more than one 
mechanism has to be involved in cholesterol-induced regulation of different ion channels. 
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Studies from our laboratory have shown that many major and important ion channels are 
regulated by changes in the level of membrane cholesterol (Epshtein et al., 2009; Levitan, 
2009; Levitan et al., 2010; Rosenhouse-Dantsker et al., 2011; Singh et al., 2009b; Singh et al., 
2011). In general three different mechanisms may be involved in regulation of ion channels 
by cholesterol: (i) specific interactions (ii) changes in the physical properties of the 
membrane bilayer and (iii) maintaining the scaffolds for protein-protein interactions. 
Furthermore, our recent data for the first time demonstrate a specific cholesterol-channel 
binding (Singh et al., 2011). One possibility is that cholesterol may interact directly and 
specifically with the transmembrane domains of the channels protein. Direct interaction 
between channels and cholesterol as a boundary lipid was first proposed in a “lipid belt” 
model by (Marsh and Barrantes, 1978) suggesting that cholesterol may be a part of a lipid 
belt or a “shell” constituting the immediate perimeter of the channel protein. Moreover, 
studies from our laboratory demonstrated that inwardly-rectifying K+ channel are sensitive 
to the chiral nature of the sterol analogue providing further support for the hypothesis that 
sensitivity of these channels to cholesterol can be due to specific sterol-protein interactions 
(Romanenko et al., 2002). An alternative mechanism proposed by Lundbaek and colleagues 
(Lundbaek and Andersen, 1999) suggested that cholesterol may regulate ion channels by 
hydrophobic mismatch between the transmembrane domains and the lipid bilayer. More 
specifically, it was proposed that when a channel goes through a change in conformation 
state within the viscous medium of the lipid membrane it may induce deformation of the 
lipid bilayer surrounding the channel. If this is the case, then a stiffer less deformable 
membrane will increase the energy that is required for the transition (Levitan et al., 2010). It 
is important to note that these mechanisms are not mutually exclusive. A lipid shell 
surrounding a channel may also affect the hydrophobic interactions between the channels 
and the lipids and increase the deformation energy required for the transitions between 
closed and open states. Finally, obviously, cholesterol may also affect the channels indirectly 
through interactions with different signalling cascades. 
1.7 Cholesterol and oxysterol as major oxidized component in oxidized LDL 
Oxidation of LDL is considered as the major risk factors for the development of coronary 
artery disease (CAD) and plaque formation (reviewed in (Berliner et al., 2001; Levitan and 
Shentu, 2011). Indeed, elevated levels of oxLDL are associated with an increased risk of CAD 
(Toshima et al., 2000) and correlate with plasma hypercholesterolemia both in humans (van 
Tits et al., 2006) and in the animal models of atherosclerosis (Hodis et al., 1994; Holvoet et al., 
1998). It is also well-known that exposure to oxLDL induces an array of proinflammatory and 
proatherogenic effects but the mechanisms that underlie oxLDL-induced effects remain 
controversial. Most of studies involving oxLDL are based on ex-vivo oxidation of LDL. The 
term oxidized LDL is used to describe LDL preparations which have been oxidatively 
modified ex vivo under defined conditions, or isolated from biological sources.  
The most typical procedure of LDL oxidation ex vivo is incubation of LDL with metal ions, 
Cu2+ in particular, that leads to the generation of multiple oxidized products in the LDL 
particle, including oxysterols, oxidized phospholipids, and modified apolipoprotein B 
(reviewed in (Burkitt, 2001; Levitan and Shentu, 2011). The oxidized LDL preparations 
described in the literature are broadly divided into two main categories: “minimally 
modified LDL” (MM-LDL) and (fully or extensively) oxidized LDL (oxLDL) based on the 
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degree of LDL oxidation. Cu2+ oxidation of LDL can generate both minimally modified and 
fully oxidized LDLs depending on the duration of the exposure and ion concentration. Two 
other procedures that are also used to generate oxLDL ex vivo are enzymatic oxidation by 
15-lypoxygenase or myeloperoxidase or by incubating LDL with 15-lypoxygenase 
expressing cells (Boullier et al., 2006). It is important to note that while it is controversial 
whether Cu2+ oxidation occurs in vivo, it was shown that there are significant similarities 
between Cu2+ oxidized LDL and oxLDL found in atherosclerotic lesions (Yla-Herttuala et al., 
1989). However, oxidation of LDL is a complex process that yields an array of bioactive 
compounds with different biological properties and its composition depends on the 
degree of LDL oxidation It is known that oxLDL includes various oxidized products that 
are divided into neutral lipids, a group that includes cholesterol and cholesterol ester, and 
phospholipids that include SM, PE, LPC and PC (Subbanagounder et al., 2000). Our recent 
studies have identififed five major oxysterols in strongly oxidized LDL (16 hours of 
oxidation data submitted for publication) by the GC analysis: 7ǂ-hydroxycholesterol , 7ǃ-
hydroxycholesterol, cholesterol 5ǂ,6ǂ- and 5ǃ,6ǃ-epoxides, and 7-ketocholesterol similar 
to earlier studies (Brown et al., 1996). Our recent unpublished data showed that the most 
abundant oxysterol is 7ǃ-hydroxycholesterol, followed by 7-ketocholesterol with 7ǂ- 
hydroxycholesterol and cholesterol 5ǃ,6ǃ-epoxide representing minor oxysterols in 
oxLDL. Two oxysterols, 25-hydroxycholesterol and 27-hydroxycholesterol do not 
constitute significant components of oxLDL complex, but were found in human 
atherosclerotic lesions (Bjorkhem et al., 1994; Zidovetzki and Levitan, 2007). 27-
hydroxycholesterols, specially is abundant in human atherosclerotic lesions and 
macrophage-derived foam cells (Brown and Jessup, 1999). 
1.8 Impact of oxLDL on cholesterol-rich membrane rafts  
Membrane rafts were originally described as cholesterol- and sphingolipid-rich 
microdomains that provide platforms for protein-protein interactions in multiple signaling 
cascades (Brown and London, 1998; Simons and Gerl, 2010; Simons and Ikonen, 1997). 
Membrane rafts are small (10–200 nm), heterogeneous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalize cellular processes" (Pike, 2006). Most 
recently, Simons and Gerl (Simons and Gerl, 2010) further defined membrane rafts as 
“dynamic, nonoscale, sterol-sphingolipid-enriched, ordered assembles of proteins and 
lipids” that are regulated by specific lipid-lipid, protein-lipid, and protein-protein 
interactions (Simons and Gerl, 2010). The goal of this section of book chapter is to discuss 
the recent advances in our understanding of the impact of oxLDL on membrane rafts. 
Oxysterols are found in abundance in Cu2+-oxidized LDL, in which cholesterol is oxidized 
preferably at 7 positions resulting in the generation of 7-ketocholesterol, 7β-
hydroxycholesterol, and 7-hydroxycholesterol (Brown and Jessup, 1999). In addition, 27-
hydroxycholesterol, that is, generated in vivo, has been shown to accumulate in foam cells in 
atherosclerotic lesions (Brown and Jessup, 1999). Several studies have shown that oxysterols 
result in inhibition of cholesterol efflux in the mouse and it was suggested that impairment 
of cholesterol homeostasis by the inhibition of cholesterol efflux may be mechanism by 
which oxysterols affect cellular function (Kilsdonk et al., 1995; Terasaka et al., 2008). 
Interestingly, 7-ketocholesterol was shown to deplete cholesterol specifically from the raft 
domains in human macrophages (Gaus et al., 2004) and disrupt lipid packing of the 
immunological synapses in sterol-enriched T lymphocytes (Rentero et al., 2008) and in 
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cholesterol-rich membrane domains in endothelial cells (Shentu et al., 2010). These 
observations suggest that incorporation of oxysterols may also play an important role in 
oxLDL-induced disruption of cholesterol-rich membrane domains. 
1.9 Manipulation of cholesterol in cellular system (in vitro and in vivo models) 
The physiological importance of cholesterol in the cell plasma membrane has attracted 
increased attention in recent years. Consequently, the use of methods of controlled 
manipulation of membrane cholesterol content has also increased sharply, especially as a 
method of studying putative cholesterol-enriched cell membrane domains (rafts). The most 
common means of modifying the cholesterol content of cell membranes is the incubation of 
cells or model membranes with cyclodextrins, a family of compounds, which, due to the 
presence of relatively hydrophobic cavity, can be used to extract cholesterol from cell 
membranes (Zidovetzki and Levitan, 2007). Under conditions commonly used for 
cholesterol extraction, cyclodextrins may remove cholesterol from both raft and non-raft 
domains of the membrane as well as alter the distribution of cholesterol between plasma 
and intracellular membranes. In addition, other hydrophobic molecules such as 
phospholipids may also be extracted from the membranes by cyclodextrins. Here, we 
discuss useful control strategies that may help to verify that the observed effects are due 
specifically to cyclodextrin-induced changes in cellular cholesterol. 
The high affinity of methyl-ǃ-cyclodextrin (MǃCDs) for cholesterol can be used not only to 
remove cholesterol from the biological membranes but also to generate cholesterol inclusion 
complexes that donate cholesterol to the membrane and increase membrane cholesterol 
level. MǃCD-cholesterol inclusion complexes are typically generated by mixing cholesterol 
suspension with a cyclodextrin solution as described earlier (Christian et al., 1997; Klein et 
al., 1995; Levitan et al., 2000; Zidovetzki and Levitan, 2007). The ratio between the amounts 
of cholesterol and cyclodextrin in the complex determines whether it will act as cholesterol 
acceptor or as cholesterol donor (Zidovetzki and Levitan, 2007). The efficiency of cholesterol 
transfer from MǃCD inclusion complex to biological membranes depends on 
MǃCD:cholesterol molar ratio, MǃCD-cholesterol concentration, and duration of the 
exposure (Zidovetzki and Levitan, 2007). Thus, it is important to note that exposing cells to 
MǃCD-cholesterol complexes that contain saturating amounts of cholesterol typically results 
not just in replenishing cholesterol to control levels but in significant cholesterol enrichment. 
Cholesterol enrichment is observed even if the cells were first depleted of cholesterol and 
then exposed to MǃCD-cholesterol complexes. ApoE -/- mice cholesterol ester transfer 
protein (CETP) knock out mice are ideal in vivo animal model to study cholesterol 
biosynthetic pathway and its regulation. Our recent study revealed that WT and ApoE -/- 
mice fed on normal chow diet for 4 weeks, showing a significant increase in the level of 
cholesterol in ApoE -/- mice as compared to WT (Shentu et al., 2011). 
1.10 Treatment of hypercholesterolemia  
Reductions in circulating cholesterol levels can have profound positive impacts on 
cardiovascular disease, particularly on atherosclerosis, as well as other metabolic 
disruptions of the vasculature. Control of dietary intake is one of the easiest and least cost 
intensive means to achieve reductions in cholesterol. But in most of the alleviated levels of 
cholesterol cannot be controlled merely with exercise. Drug therapy is very important to 
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avoid the cardiovascular effects of high cholesterol levels in such patients. In this section of 
the book chapter, we have discussed the regulation cholesterol by drugs as well as will 
review recent work from our laboratory for the regulation of cholesterol by natural products 
such as tea/green tea, policosanol and garlic compounds.  
1.10.1 Regulation of cholesterol by natural products 
In this section of book the regulation of cholesterol by natural products, tea, policosanol and 
garlic is discussed.  
1.10.1.1 Tea and tea compounds 
Epidemiological studies have indicated that tea consumption is associated with a lower risk 
of cardiovascular disease. This decreased risk is attributed to the ability of tea to lower 
serum cholesterol levels, and several clinical studies have demonstrated that black tea can 
lower serum total- and LDL-cholesterol (Davies et al., 2003; Maron et al., 2003). Green tea 
has been shown to be hypocholesterolemic in animal studies, with the bulk of evidence 
indicating that tea polyphenols reduce the absorption of dietary and biliary cholesterol and 
promote its fecal excretion (Koo and Noh, 2007).. 
Feeding studies have been equivocal on the ability of green tea extract to inhibit cholesterol 
synthesis. Although a recent study by Bursill and colleagues (Bursill et al., 2007) showed a 
decrease in serum lathosterol (an indicator of whole body cholesterol synthesis) in rabbits 
fed a green tea extract, a similar study with rats by these investigators (Bursill and Roach, 
2007) was unable to demonstrate a decrease in this serum sterol, despite significant 
reductions in hepatic cholesterol levels and an increase in LDL receptor expression. A 
feeding study by Chan et al. (Chan et al., 1999) was similarly unable to demonstrate an effect 
of green tea extract on hepatic HMG-CoA reductase activity. Measuring cholesterol 
synthesis in vivo is difficult, whereas in vitro studies are more tractable. In this regard, 
Gebhardt and colleagues reported that several common polyphenols (luteolin, quercetin) 
were able to decrease cholesterol synthesis when added to cultured hepatocytes or 
hepatoma cell cultures (Gebhardt, 2003). This inhibition appeared to occur at the level of 
HMG-CoA reductase. Tea polyphenols (Abe et al., 2000), as well as the simple polyphenol 
resveratrol have been shown to directly inhibit squalene monooxygenase, a rate-limiting 
downstream enzyme in cholesterol synthesis. Two studies by Bursill and colleagues (Bursill 
et al., 2001; Bursill and Roach, 2006) demonstrated an increase in HMG-CoA reductase and 
LDL-receptor mRNA in HepG2 cells incubated with green tea extract or its principal 
component, epigallocatechin gallate (EGCG), and a decrease in cellular lathosterol, 
indicating that cholesterol synthesis was inhibited in treated cells (Singh et al., 2009a). 
Together, these studies suggest that green tea polyphenols are inhibitory to cholesterol 
synthesis by inhibiting HMGCoA reductase (Singh et al., 2009a). Moreover, the effect of 
black tea extract, which consists predominantly of a diverse mixture of polymerized 
polyphenols termed theaflavins and thearubigins, has not been examined, despite the recent 
clinical evidence that black tea can modestly reduce serum cholesterol levels. 
1.10.1.2 Decrease in cholesterol level by policosanol 
Policosanol, a mixture of very long-chain alcohols isolated from sugarcane, at doses of 10 to 
20 mg/day has been shown to lower total and LDL cholesterol by up to 30%, equivalent to 
low-dose statin therapy (Gouni-Berthold and Berthold, 2002). In both short-term (≤12-week) 
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and long-term (up to 2-year) randomized, placebo-controlled, double-blind studies, 
policosanol lowered LDL-cholesterol in normocholesterolemic patients by an average of 
33%, and in hypercholesterolemic patients by 24% (for review, see (Gouni-Berthold and 
Berthold, 2002; Varady et al., 2003). In normocholesterolemic patients, policosanol caused a 
small and generally insignificant increase in high-density lipoprotein-cholesterol, whereas in 
seven clinical studies of dyslipidemic patients high-density lipoprotein-cholesterol was 
increased by an average of 17%. Policosanol is also effective in rabbits and monkeys, where 
it lowers blood cholesterol and reduces the development of atherosclerotic plaques (Wang et 
al., 2003), but it was found not to be effective in hamsters (Wang et al., 2003).  
The major components of policosanol are the primary alcohols octacosanol (C28; ~60%), 
triacontanol (C30; 12–14%), and hexacosanol (C26; 6–12%), with lesser amounts of other 
alcohols with chain lengths of 24 to 34 carbons (Singh et al., 2006) . The product has no evident 
toxicity and is available over-the-counter in many outlets. The active component(s) has not 
been established, but it has been shown that very long-chain alcohols can undergo oxidation to 
fatty acids with subsequent peroxisomal ǃ-oxidation, which also yields chain-shortened 
metabolites (Singh et al., 1987). D-003, a mixture of very long-chain saturated fatty acids, also 
purified from sugarcane, similarly lowers LDL and total cholesterol in normocholesterolemic 
patients (Castano et al., 2005) and in normocholesterolemic and casein-induced 
hypercholesterolemic rabbits, and a more rapid onset of effects suggests that oxidation of 
policosanols to very long-chain fatty acids may be necessary for their hypocholesterolemic 
actions (Menendez et al., 2001; Menendez et al., 2004). Several studies have demonstrated that 
policosanol inhibits cholesterol synthesis in laboratory animals and cultured cells, and it is 
thought that this is the principal mechanism by which it lowers blood cholesterol levels. In the 
latter study, policosanol did not affect the incorporation of [14C]mevalonate into cholesterol, 
indicating that policosanol was acting at or above mevalonate synthesis. However, policosanol 
did not inhibit HMG-CoA reductase (mevalonate synthase) when added to cell lysates, 
arguing against a direct interaction with this enzyme. The ability of policosanol to prevent the 
up-regulation of HMG-CoA reductase activity in these cells in response to lipid-depleted 
media suggested that policosanol suppresses HMG-CoA reductase synthesis or enhances 
enzyme degradation. Similar results were obtained with D-003 (Menendez et al., 2001), 
although neither study measured HMG-CoA reductase protein levels. Our studies explored 
that policosanol and identify the active component(s) of this natural product inhibits 
cholesterol synthesis by inhibiting HMGCoA reductase enzyme (Singh et al., 2006).  
1.10.1.3 Inhibition of cholesterol biosynthesis by garlic 
Garlic is rich in sulfur-containing compounds, principally S-allylcysteine and alliin, the 
latter of which is rapidly metabolized when garlic is crushed and alliinase is released. The 
highly reactive sulfenic acid that is formed from alliin condenses to allicin, which then 
rapidly recombines to various di- and tri-sulfides, depending on conditions. Ultimately 
these compounds are believed to yield allyl mercaptan and allyl methyl sulfide, which can 
react with cellular components or be eliminated on the breath. The organosulfur compounds 
formed in garlic are highly reactive with other sulfhydryl compounds, including cysteines 
found in proteins, and it is likely that the chemical modification of enzyme-sulfhydryls is 
responsible for the purported therapeutic effects of garlic. The question of which 
compounds are most important to the therapeutic effects of garlic remains unresolved, 
although several studies have shown that the diallyl disulfides, allyl mercaptan, and S-
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alk(en)yl cysteines are effective inhibitors of cholesterol synthesis in cells (Gebhardt and 
Beck, 1996; Liu and Yeh, 2000; Singh and Porter, 2006). Similarly, the enzyme targets that 
mediate the effects of garlic have not been identified.  
Our studies with hepatoma cells in which cholesterol and intermediates are radiolabeled 
and identified by coupled gas chromatography–mass spectrometry reveal that garlic 
causes the accumulation of sterol 4ǂ-methyl oxidase substrates and that an allyl disulfide 
or allyl sulfhydryl group is necessary for inhibition by garlic-derived compounds (Singh 
and Porter, 2006).  
1.10.2 Treatment of Hypercholesterolemia by available drug therapy 
Drug treatment to lower plasma lipoprotein /or cholesterol is primarily aimed at reducing 
the risk of athersclerosis and subsequent coronary artery disease that exists in patients with 
elevated circulating lipids. Drug therapy usually is considered as an option only if non-
pharmacologic interventions (altered diet and exercise) have failed to lower plasma lipids. 
1.10.2.1 Members of statins family 
These are fungal HMG-CoA reductase (HMGR) inhibitors from members of statins family. 
Atorvastin (Lipitor), simvastatin (Zocor) and lovastatin (Mevacor) belongs to this family, are 
widely used for lowering the plasma cholesterol. During the course of treatment, cellular 
uptake of LDL from plama is significantly increased, since the intracellular synthesis of 
cholesterol is inhibited as cells are dependent on extracellular sources of cholesterol. 
Important isoprenoid compounds require mevalonate as the precursor as a result long term 
treatment carry some risk of toxicity. A component of the natural cholesterol lowering 
supplement, red yeast rice, is in fact a statin-like compound. Other beneficial effects of 
statins other than lowering blood cholesterol levels via their actions on HMGR are ability to 
reduce the prenylation of numerous pro-inflammatory modulators. Thus, inhibition of this 
post-translational modification by the statins interferes with the important functions of 
many signaling proteins which is manifest by inhibition of inflammatory responses. 
1.10.2.2 Fibrates compounds 
Second group drugs belongs to a series of compounds are derivatives of fibric acid and 
although known since 1930 but identified as cholesterol lowering drugs very recently. 
Fibrates are activators of the peroxisome proliferator activated receptor-ǂ (PPARǂ) class of 
proteins and are classified as nuclear receptor co-activators. Fibrates result in activation of ǃ-
oxidation and thereby decreasing the level of triacyl glycerol and cholesterol rich VLDL in 
liver as well as enhances the clearance of chylomicrons remnants, and increase in the level of 
HDLs. These drugs are also known to increase the lipase activity which in turn promotes 
rapid VLDL turnover. Gemifibrozil (Lopid) and Fenofibrate (Tricor) are two therapeutic 
drugs available in the market.  
1.10.2.3 Cholestyramine or colestipol 
Cholestyramine or colestipol (resins) compounds are nonabsorbable resins that bind bile 
acids which are then not reabsorbed by the liver but excreted. The drop in hepatic 
reabsorption of bile acids releases a feedback inhibitory mechanism that had been inhibiting 
bile acid synthesis. As a result, a greater amount of cholesterol is converted to bile acids to 
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maintain a steady level in circulation. Additionally, the synthesis of LDL receptors increases 
to allow increased cholesterol uptake for bile acid synthesis, and the overall effect is a 
reduction in plasma cholesterol. This treatment is ineffective in homozygous FH patients 
since they are completely deficient in LDL receptors. 
1.10.2.4 Ezetimibe 
This drug is sold under the trade names Zetia® or Ezetrol® and is also combined with the 
statin drug simvastatin and sold as Vytorin® or Inegy®. Ezetimibe functions to reduce 
intestinal absorption of cholesterol, thus effecting a reduction in circulating cholesterol. The 
drug functions by inhibiting the intestinal brush border transporter involved in absorption of 
cholesterol. This transporter is known as Niemann-Pick type C1-like 1 (NPC1L1). NPC1L1 is 
also highly expressed in human liver. The hepatic function of NPC1L1 is presumed to limit 
excessive biliary cholesterol loss. NPC1L1-dependent sterol uptake is regulated by cellular 
cholesterol content. In addition to the cholesterol lowering effects that result from inhibition of 
NPC1L1, its' inhibition has been shown to have beneficial effects on components of the 
metabolic syndrome, such as obesity, insulin resistance, and fatty liver, in addition to 
atherosclerosis. Ezetimibe is usually prescribed for patients who cannot tolerate a statin drug 
or a high dose statin regimen. There is some controversy as to the efficacy of ezetimibe at 
lowering serum cholesterol and reducing the production of fatty plaques on arterial walls. The 
combination drug of ezetimibe and simvastatin has shown efficacy equal to or slightly greater 
than atorvastatin (Lipitor®) alone at reducing circulating cholesterol levels. 
1.10.2.5 New approaches for the treatment of hypercholesterolemia 
In the last decade, a number of epidemiological and clinical studies have demonstrated a 
direct correlation between the circulating levels of HDL cholesterol and a reduction in the 
potential for atherosclerosis and coronary heart disease (CHD). Individuals with low levels 
of HDL (below 40mg/dL) are at higher risk of coronary heart disease CHD) then individual 
with level above 50mg/dL. Clinical studies have demonstrated that infusion of HDL 
component, apolipoprotein A-1 (apoA-1) in patients, significantly increases the level of 
HDL. The newest strategies are targeted to up regulate the level of HDL cholesterol instead 
of decreasing the level of total cholesterol. Cholesterol ester transfer protein (CETP) is 
secreted primarily from the liver and plays a critical role in HDL metabolism by facilitating 
the exchange of cholesteryl esters (CE) from HDL for triglycerides (TG) in apoB containing 
lipoproteins, such as LDL and VLDL. The activity of CETP directly lowers the cholesterol 
levels of HDLs and enhances HDL catabolism by providing HDLs with the TG substrate of 
hepatic lipase. Thus, CETP plays a critical role in the regulation of circulating levels of HDL, 
LDL, and apoA-I. It has also been shown that in mice naturally lacking CETP most of their 
cholesterol is found in HDL and these mice are relatively resistant to atherosclerosis. CETP 
inhibitors have failed in the clinical trials as their use has increased negative cardiovascular 
events and death rates in test subjects.  
2. Conclusion  
Cholesterol is an essential component in cell membrane, as a precursor for the synthesis of 
steroid hormones vitamin D, and bile acids that aid in digestion and cellular signal 
transduction. Half of the cholesterol is de novo synthesized in liver and is transported 
through various lipoprotein. Dysfunction in cholesterol metabolism can lead to 
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hypercholesterolemia which is a major factor in the development of atherosclerosis. Mode of 
intracellular and extracellular cholesterol transport through acceptors-donors and thereafter 
cholesterol trafficking pathways are highly co-ordinated with each other, regulated at 
enzymatic/transcriptional level and diverse functions of cholesterol in our body. Taken 
together, this book chapter addressed recent advances in cholesterol metabolism related to 
absorptions, biosynthesis, transport, excretion and therapeutic targets for new drugs and 
natural compounds.  
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